Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.42 |
| ▸ | INSR | P06213 | 3/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 9/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917073 | 1.00 | KDR (0.42) | KDRINSRPTK2BPTK2GSK3A | |
| SCHEMBL1916948 | 0.81 | JAK3 (0.44) | KDRPTK2BGSK3AGSK3BSYK | |
| SCHEMBL1916950 | 0.81 | JAK3 (0.44) | KDRPTK2BGSK3AGSK3BSYK | |
| SCHEMBL1917745 | 0.80 | SYK (0.45) | GSK3AGSK3BSYKPLK1LCK | |
| SCHEMBL1917742 | 0.80 | SYK (0.45) | GSK3AGSK3BSYKPLK1LCK | |
| SCHEMBL1916873 | 0.80 | GSK3B (0.46) | PTK2BGSK3AGSK3BSYKPLK1 | |
| SCHEMBL1916265 | 0.78 | GSK3B (0.47) | GSK3AGSK3BLCKJAK3 | |
| SCHEMBL1916261 | 0.78 | GSK3B (0.47) | GSK3AGSK3BLCKJAK3 | |
| SCHEMBL1917090 | 0.77 | EGFR (0.54) | KDRINSRSYKPLK1 | |
| SCHEMBL1917086 | 0.77 | EGFR (0.54) | KDRINSRSYKPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | KDR 607/4885INSR 320/4885PTK2B 1613/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | KDR 130/4885INSR 3/4885PTK2B 954/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | KDR 607/4885INSR 320/4885PTK2B 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.